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We have shown that combining cetuximab-based therapy with an anti-IGF-1R monoclonal 
antibody (dalotuzumab) did not improve the outcome of chemorefractory, KRAS exon 2 
mutant, metastatic colorectal cancer patients. By using a large prospective dataset we have also 
found that family members of the IGF signalling pathway were more expressed in KRAS wild-
type compared to KRAS exon 2 mutant colorectal cancers while IGF-1 expression was higher 
in rectal compared to colon tumours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
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Limited data are available on the efficacy of anti-IGF-1R agents in KRAS mutant colorectal 
cancer (CRC). We analysed outcome of 69 chemorefractory, KRAS exon 2 mutant CRC 
patients who were enrolled in a double-blind, randomised, phase II/III study of irinotecan and 
cetuximab plus dalotuzumab 10 mg/kg once weekly (arm A), dalotuzumab 7.5 mg/kg every 
second week (arm B) or placebo (arm C). Objective response rate (5.6% vs. 3.1% vs. 4.8%), 
median progression-free survival (2.7 vs. 2.6 vs. 1.4 months) and overall survival (7.8 vs. 10.3 
vs. 7.8 months) were not statistically significantly different between treatment groups. Most 
common grade ≥3 treatment-related toxicities included neutropenia, diarrhoea, 
hyperglycaemia, fatigue and dermatitis acneiform. Expression of IGF-1R, IGF-1, IGF-2 and 
EREG by quantitative real-time polymerase chain reaction was assessed in 351 patients from 
the same study with available data on KRAS exon 2 mutational status. Median cycle threshold 
values for all biomarkers were significantly lower (i.e., higher expression, p<0.05) among 
patients with KRAS wild-type compared to those with KRAS exon 2 mutant tumours. No 
significant changes were found according to location of the primary tumour with only a trend 
towards lower expression of IGF-1 in colon compared to rectal cancers (p=0.06). Albeit limited 
by the small sample size, this study does not appear to support a potential role for anti-IGF-1R 
agents in KRAS exon 2 mutant CRC. Data on IGF-1R, IGF-1 and IGF-2 expression here 
reported may be useful for patient stratification in future trials with inhibitors of the IGF 
pathway.     
 
 
 
 
 
Introduction  
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The insulin receptor (IR) and the type I insulin-like growth factor receptor (IGF-1R) are 
membrane tyrosine kinase receptors that are expressed in both normal tissues and cancer cells.1 
While in the former they regulate physiological processes such as glucose homeostasis, in the 
latter they are thought to be involved in the promotion of carcinogenesis and tumour 
proliferation.1,2 Oncogenic signaling through this family of receptors is mediated by three main 
ligands (i.e., insulin, IGF-1 and IGF-2) through endocrine, autocrine and paracrine mechanisms 
and largely converges towards the RAS-RAF-MEK-ERK and PI3K-AKT pathways.3 Based on 
this biological rationale and supportive evidence from preclinical experiments with IR/IGF-1R 
inhibitors, targeting this signaling pathway has been considered an attractive option in the 
development of novel anti-cancer therapeutics.4,5 However, clinical studies have failed to 
confirm the pre-clinical promise with IR/IGF-1R targeted agents showing no benefit in a 
number of tumour types including colorectal cancer (CRC).6-20  
 
Suboptimal patient selection is one of the hypotheses to explain failure of IGF-1R inhibitors in 
the clinical setting. So far studies have been largely conducted in unselected patient populations 
and preclinical data as well as retrospective analyses of prospective trials suggest that 
enrichment strategies using circulating or tissue biomarkers may be key to the success of such 
agents.20,22-24 Indeed, the relative influence of the IGF signalling axis on the mechanisms of 
tumour growth and progression may vary according to a number of tumour-related factors, 
either clinical or molecular.20,25,26 
 
KRAS is a downstream effector of both epidermal growth factor receptor (EGFR) and IGF-1R 
and is mutated in approximately 35-40% of CRC patients.27 Whilst mutation of KRAS is now 
a well-established predictive marker of resistance to anti-EGFR monoclonal antibodies28, 
preclinical studies suggest that the anti-tumour activity of anti-IGF-1R agents, either alone or 
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in combination with inhibitors of the RAS-RAF-MEK-ERK pathway, is independent of KRAS 
status.25,26 Furthermore, the functional relevance of the IGF-1R/PI3K signalling axis as well as 
the therapeutic potential of its inhibition have been reported to be higher in KRAS mutant 
compared to KRAS wild-type cells.25,26 To our knowledge, only one study has selectively 
reported on the outcome of patients treated with anti-IGF-1R-based regimens in KRAS mutated 
metastatic CRC.18 Also, data on the expression of members of the IGF-1R pathway by KRAS 
status in large CRC patient series are lacking.   
 
We have recently reported the results of a large randomised, placebo-controlled, three-arm, 
phase II/III study (n=344) where two schedules of the anti-IGF-1R humanised IgG1 
monoclonal antibody dalotuzumab were assessed in combination with irinotecan and 
cetuximab in chemorefractory KRAS exon 2 wild-type metastatic CRC.20 Neither 
investigational arm was found to be superior to standard therapy and an unexpected detrimental 
effect of weekly dalotuzumab on patients’ outcome observed; therefore recruitment was 
terminated after a pre-planned interim analysis. This study commenced recruitment prior to the 
introduction of KRAS characterisation and included a cohort of patients with KRAS exon 2 
mutated CRC.  
 
In this article we report efficacy and safety data from patients with KRAS mutated metastatic 
CRC who were enrolled in this study before a protocol amendment restricted eligibility to 
patients with KRAS wild-type tumours. Moreover, we report on tumour expression of IGF-1R, 
IGF-1, IGF-2 and epiregulin (EREG) as assessed in the whole study population. 
 
 
Materials and methods  
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Eligibility criteria 
Eligibility criteria have been previously reported in detail.20 In short, patients were deemed 
eligible for this study if they were ≥18 years old, had histologically confirmed diagnosis of 
measurable metastatic CRC, failed prior irinotecan- and oxaliplatin-containing regimens, had 
progressed on or within three months of last line of therapy, had no previous exposure to IGF-
1R or EGFR inhibitors and their Eastern Cooperative Oncology Group (ECOG) performance 
status was ≤1. Although availability of archival tumour tissue was mandatory, assessment of 
KRAS status was not part of the study screening procedures until 2009 when recruitment was 
restricted to patients with KRAS exon 2 wild-type tumours. 
 
Study design  
Study design and procedures have been previously reported in detail.20 In summary, this was 
an international, multicentre, double-blind, randomised, phase II/III study with a short safety 
run-in conducted in 55 sites across four continents. Eligible patients were randomised in a 1:1:1 
ratio to receive irinotecan and cetuximab plus dalotuzumab 10 mg/kg once weekly (arm A), 
irinotecan and cetuximab plus dalotuzumab 15 mg/kg loading dose and then 7.5 mg/kg every 
second week (arm B) or irinotecan and cetuximab plus placebo (arm C). Cetuximab was 
administered at a dose of 250 mg/m2 once weekly (loading dose of 400 mg/m2) while the same 
dose and schedule as had been previously given during the patient’s pre-study therapy was used 
for irinotecan. Treatment was administered until disease progression, unbearable toxicity, or 
consent withdrawal. Response Evaluation Criteria in Solid Tumors (RECIST) v1.029 was used 
to assess tumour response (central independent review) with computed tomography (CT) or 
magnetic resonance imaging (MRI) scans performed every 6 weeks for the first 48 weeks and 
every 3 months thereafter. The study was approved by an independent ethics committee or 
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institutional review board at each site. All patients provided written informed consent. This 
study was registered at ClinicalTrials.gov (NCT00614393).  
 
KRAS testing and exploratory biomarker analyses 
Throughout the study, KRAS exon 2 mutations were screened for in a central laboratory using 
the TheraScreen KRAS test (Qiagen, Manchester, UK). In post-hoc exploratory analyses IGF-
1R, IGF-1, IGF-2 and EREG expression were assessed by quantitative real-time polymerase 
chain reaction (qRT-PCR) (Almac Diagnostics, Craigavon, UK) using RNA extracted from 
formalin-fixed, paraffin-embedded tissue.20  
 
Statistical design  
The statistical design of the main study has been previously reported in detail.20 The dual 
primary endpoints in KRAS mutant patients were progression-free survival (PFS) and overall 
survival (OS). PFS was defined as the time from randomisation to the first documented disease 
progression (as per independent review), or death due to any cause, whichever occured first. 
OS was defined as the time from randomisation to death due to any cause. Patients without a 
documented event were censored at the date of the last follow-up. PFS and OS were analysed 
using Kaplan Meier methods and comparison between groups used Cox regression analysis. 
Chi squared test was used for comparison of objective response rates between treatment groups. 
IGF-1, IGF-2, IGF-1R and EREG expression according to KRAS status and site of tumour was 
assessed by Wilcoxon rank sum test. Also, a pairwise correlation analysis of biomarker 
expression in individual patients was performed (a correlation coefficient of 0.00, ≥0.30, ≥0.50. 
≥0.70 and 1.00 indicated no linear relationship, weak positive linear relationship, moderate 
positive linear relationship, strong positive linear relationship and perfect positive linear 
relationship, respectively).  
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Results 
From 2008 through 2009 (before study recruitment was limited to patients with KRAS exon 2 
wild-type tumours), 242 patients were enrolled in the trial. Of these, 71 were found to have 
tumours harbouring a mutation within exon 2 of the KRAS gene. Eighteen were randomised to 
arm A, 32 to arm B and 21 to arm C. Baseline demographics and clinical characteristics of 
these patients are presented in Table 1 including 2 patients who were found to be ineligible and 
not included in the primary efficacy analysis. 
 
Dalotuzumab/placebo was administered for a median of 11.9 weeks (range 1.0 – 53.3), 8.0 
weeks (range 1.0 – 53.3) in arm A, 10.0 weeks (range 3.0 – 48.0) in arm B and 11.4 weeks 
(range 1.0 – 40.0) in arm C. In the eligible population, objective responses as assessed by 
independent radiological review were observed in 3 patients, 1 for each arm (response rate: 
5.6% in arm A, 3.1% in arm B, 4.8% in arm C). At the time of this analysis, 55 events were 
recorded for PFS and 54 for OS. Median PFS in the control arm was 1.4 months compared with 
2.7 months [HR 0.75 (95% CI: 0.35 – 1.58); p=0.45] and 2.6 months [HR 1.08 (95% CI: 0.56 
– 2.09); p=0.56] in arm A and B, respectively (Figure 1). In the same treatment groups, median 
OS was 7.8, 7.8 and 10.3 months. At 1 year, 25% of patients in the control arm were alive 
compared to 50.0% [HR 0.88 (95% CI: 0.42 – 1.84); p=0.73] and 22.6% [HR 0.96 (95% CI: 
0.49 – 1.90); p=0.92] in arm A and B, respectively. Results were not different when the 
outcome of all dalotuzumab-treated patients (arm A + arm B, n=49) was compared with that 
of arm C patients (n=20). In the former group median PFS and OS were 2.6 and 10.3 months, 
respectively, compared with 1.4 [HR 0.94 (95% CI: 0.51 – 1.74); p=0.84] and 7.8 months [HR 
0.93 (95% CI: 0.49 – 1.74); p=0.82], respectively, in the latter group (Supplementary Figure 
1).  
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Grade ≥3 toxicity was observed in 72.2% of patients in arm A, 53.1% in arm B, and 52.4% in 
arm C. Most common grade ≥3 treatment-related adverse events by study arm are reported in 
Table 2 and included neutropenia, diarrhoea, hyperglycaemia, fatigue and dermatitis 
acneiform. In only one case, treatment was discontinued as a result of a drug-related adverse 
event.   
  
IGF-1R, IGF-1 and IGF-2 expression 
Expression of IGF-1R, IGF-1 and IGF-2 by qRT-PCR was assessed in 357, 354 and 354 
eligible patients who were randomised in the study (either before or after study protocol 
amendment in 2009), respectively. Of these, 351 were tested for KRAS exon 2 mutation [285 
(81.2%) KRAS wild-type and 66 (18.8%) KRAS mutant] while 353 had available information 
regarding the site of the primary tumour (216 (61.2%) colon and 137 (38.8%) rectum).    
 
Expression of IGF-1R, IGF-1 and IGF-2 by tumour site and/or KRAS status is presented in 
Figure 2-4. Median cycle threshold (Ct) values are inverse to the amount of mRNA, therefore 
lower values indicate high amounts of mRNA while higher values indicate lower amounts of 
mRNA. No difference between colon and rectal cancers were observed with regards to the level 
of IGF-1R [Ct values: 5.3 (interquartile range (IQR): 4.4 – 6.5) and 5.4 (IQR: 4.3 – 6.4), 
respectively, p=0.71] and IGF-2 [Ct values: 1.7 (IQR: 0.5 – 2.6) and 1.4 (IQR: 0.04 – 2.3), 
respectively, p=0.18]. IGF-1 expression appeared to be higher in rectal cancers [Ct value: 3.2 
(IQR: 2.1 – 4.7)] than in colon cancers [Ct value: 3.6 (IQR: 2.4 – 5.0)] and this difference 
approached statistical significance (p=0.06). The analysis by KRAS status showed that all 
members of the IGF pathway were significantly more expressed in KRAS wild-type tumours 
[Ct values: IGF-1R: 5.0 (IQR: 4.2 – 6.0); IGF-1: 3.2 (IQR: 2.0 – 4.5); IGF-2: 1.4 (IQR: 0.3 – 
2.3)] compared to KRAS exon 2 mutated tumours [Ct values: IGF-1R: 6.6 (IQR: 5.9 – 7.8); 
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IGF-1: 4.9 (IQR: 3.7 – 5.9); IGF-2: 2.0 (IQR: 0.9 – 3.0)] (p values: <0.001, <0.001 and 0.02, 
respectively). This association remained evident when the analysis was restricted to the group 
of patients with colon cancers [Ct values: IGF-1R: 5.0 (IQR: 4.2 – 6.1) vs. 6.8 (IQR: 5.9 – 8.0), 
p<0.001; IGF-1: 3.4 (IQR: 2.2 – 4.6) vs. 5.2 (IQR: 4.2 – 6.3), p<0.001; IGF-2: 1.5 (IQR: 0.4 – 
2.5) vs. 2.3 (IQR: 1.7 – 3.1), p=0.02]. However, in the group of patients with rectal cancers, 
this association was observed only for IGF-1R [Ct values: 4.8 (IQR: 4.1 – 5.8) vs. 6.5 (IQR: 
5.8 – 7.7), p<0.001] and IGF-1 [Ct values: 3.0 (IQR: 1.8 – 3.9) vs. 4.8 (IQR: 3.2 – 5.6), p<0.001] 
but not for IGF-2 [Ct values: 1.4 (IQR: 0.0 – 2.2) vs. 1.6 (IQR: 0.1 – 2.9), p=0.33].  
 
EREG expression 
Expression of EREG by qRT-PCR was assessed in 354 eligible patients. Of these, 351 were 
tested for KRAS exon 2 mutation [285 (81.2%) KRAS wild-type and 66 (18.8%) KRAS mutant] 
while 353 had available information regarding the site of the primary tumour (216 (61.2%) 
colon and 137 (38.8%) rectum).    
 
Expression of EREG by tumour site and/or KRAS status is presented in Supplementary Figure 
2. Higher levels of EREG were found in KRAS wild-type compared to KRAS mutant tumours 
[Ct values: 1.4 (IQR: 0.3 – 3.0) vs. 3.3 (IQR: 2.5 – 5.1), p<0.001]. This association remained 
evident when the analysis was restricted to the group of patients with either colon cancer [Ct 
values: 1.6 (IQR: 0.3 – 3.2) vs. 3.1 (IQR: 2.5 – 5.6), p<0.001] or rectal cancer [Ct values 1.3 
(IQR: 0.1 – 2.6) vs. 3.4 (IQR: 2.1 – 4.6), p<0.001]. In contrast, no difference in EREG 
expression was found by tumour site in KRAS unselected patients [Ct values: 2.0 (IQR: 0.7 – 
3.5) for colon and 1.8 (IQR: 0.4 – 3.4) for rectum, p=0.41].  
 
Pairwise correlation analysis 
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The results of the pairwise correlation analysis of IGF-1R, IGF-1, IGF-2 and EREG in 
individual patients are reported in Supplementary Table 1. In the overall study population a 
weak positive linear relationship was observed between IGF-1R and IGF-1 (correlation 
coefficient: 0.4318). This was maintained both in the group of patients with KRAS wild-type 
(correlation coefficient: 0.3918) and KRAS mutant tumours (correlation coefficient: 0.3347). 
Also, a similar relationship was found between IGF-1R and EREG in the overall population 
(correlation coefficient: 0.3132) and between IGF-1 and IGF-2 in patients with KRAS mutant 
tumours (correlation coefficient: 0.3329).    
 
Discussion 
The functional link between KRAS and the IGF signalling axis has long been reported, initial 
studies in murine fibroblasts showing the potential of IGF-1 to induce KRAS mRNA 
expression and KRAS mediated-progression through the late G1 phase of the cell cycle.30,31 
More recently, preclinical data has indicated that the activity of IGF-1 pathway inhibitors may 
be independent of KRAS mutational status.26 In lung cancer cell lines and genetically 
engineered mouse models dependence on IGF signalling as well as sensitivity to its inhibition 
was shown to be higher in KRAS mutated compared to KRAS wild-type tumours.25 Similarly, 
in KRAS mutated gastrointestinal cancers, the anti-IGF-1R monoclonal antibody figitumumab 
was found to induce suppression of tumour proliferation when given as monotherapy or in 
combination with chemotherapy.32  
 
Despite these preclinical data, most of the available data on the activity of anti-IGF-1R 
monoclonal antibodies in CRC are from studies conducted in populations with unselected17,33 
or KRAS wild-type tumours.17,19,20 In a randomised phase II study (n=44) of IMC-A12 with or 
without cetuximab in patients who had previously received standard chemotherapy and an anti-
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EGFR agent, only 1 out of 21 patients (5%) had partial response in the combination arm while 
no objective tumour response was reported in the monotherapy arm.17 Of note, no antitumour 
activity of the combination treatment was observed in an additional, non-randomised study arm 
restricted to patients with KRAS exon 2 wild-type tumours (n=20). In another randomised, 
placebo-controlled, phase II study, combining ganitumab with panitumumab in KRAS wild-
type chemorefractory patients did not improve response rate (22% vs. 21%), median 
progression-free survival (PFS) (5.3 vs. 3.7 months) or overall survival (OS) (10.6 vs. 11.6 
months) compared to standard therapy.19 Only the study by Cohn et al investigated IGF-1R 
inhibition in selected patients with KRAS mutated CRC.18 In this randomised, double-blind, 
phase II trial (n=104) the addition of ganitumab to FOLFIRI in patients who had progressed 
after first-line oxaliplatin-based chemotherapy failed to show superiority over standard therapy 
in terms of response rate (8% vs. 2%), median PFS (4.5 vs. 4.6 months) and OS (12.4 vs. 12.0 
months).  
 
Our analysis of the efficacy of dalotuzumab in patients with KRAS exon 2 mutated tumours is 
largely exploratory and limited by the small sample size. However, the results presented here 
are in keeping with those reported in the larger study by Cohn et al and provide additional data 
to suggest that IGF-1R/IR pathway inhibition is not of therapeutic value in KRAS mutated CRC. 
Although the lack of an extended RAS analysis has to be considered as a limitation of both 
studies, it is unlikely that selecting for patients with all RAS wild-type tumours would 
significantly change the overall findings. In this regard, it is interesting to note that in cell line 
studies the effect of KRAS mutation appeared to be heterogeneous, with KRASG13D mutation, 
but not codon 12 mutations, conferring CRC resistance to IGF-1R/IR inhibition.26 Similar to 
the efficacy data, the safety profile of dalotuzumab did not appear to be influenced by the 
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tumours KRAS status and toxicity data in this population were comparable to those we have 
previously reported in patients with KRAS wild-type tumours.20  
 
In line with the importance of the IGF signalling axis in the mechanisms of CRC carcinogenesis 
and progression34, expression of the IGF family members has been found to be higher in tumour 
tissue compared to adjacent normal mucosa.35-38 Furthermore, a gradual increase of the levels 
of the components of this oncogenic pathway has been reported along the length of the bowel, 
with IGF-1, IGF-2, IGF-1R, and IGF binding protein 3 (IGFBP-3) showing higher expression 
in rectal mucosa compared to mucosa of the ascending colon.39 To our knowledge, no large 
clinical studies have investigated possible differences in the expression of the IGF family 
members according to the anatomical site or molecular characteristics of the primary tumour. 
By analysing all assessable patients enrolled in the MK-0646-025 trial, we have shown that 
IGF-1 is significantly more expressed in rectal cancers compared to colon cancers, while all 
IGF family members investigated, with the only exception of IGF-2 in rectal cancer, are 
significantly more expressed in KRAS wild-type tumours compared to those harbouring a 
mutation in exon 2 of the KRAS gene. The main value of this analysis is in contributing further 
information on the relative biological relevance of the IGF pathway in metastatic CRC and in 
providing useful data that can be used for patient stratification/selection in future clinical trials 
with IGF-1R inhibitors. Our results could also be of clinical relevance if we consider that in 
this setting IGF-1 may serve as a biomarker to predict benefit from anti-IGF-1R agents and 
resistance to anti-EGFR monoclonal antibodies.20,40,41 As previously highlighted, however, it 
should be considered that the lack of information on the source of tumour tissue used for the 
analysis (primary tumour versus metastasis), the potential influence of pelvic radiotherapy on 
the biomarker expression values for rectal tumours and contamination by adjacent normal 
tissue may have had a potential significant impact on the overall results.20,42 Similar 
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considerations apply to the analysis of EREG in this study. It is interesting to note, however, 
that our results suggesting an association between the expression of this EGFR ligand and the 
KRAS mutational status are in line with previous studies.43  
 
Clinical and molecular data reported in this article have the merit of augmenting the existing 
body of knowledge regarding the role of the IGF system as oncogenic signalling pathways and 
potential therapeutic target in advanced CRC. Although the assumption that IGF-1R could be 
a useful target in CRC therapy has been significantly challenged by the number of negative 
studies conducted in this setting, it still remains uncertain whether refinement of patient 
selection has the potential to revert this unfavourable trend. Specific studies aiming to further 
investigate the role of the IGF axis in the mechanisms of CRC growth, progression and 
response to treatment as wells as the functional relevance of feedback activation of alternative 
oncogenic signalling pathways are desirable and likely to shed light into the next development 
of this class of agents.  
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Table 1. Baseline patient demographics and clinical characteristics (KRAS mutant cohort)    
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ARM A 
N=18 (%) 
 
ARM B 
N=32 (%) 
ARM C 
N=21 (%) 
TOTAL 
N=71 (%) 
Gender                                                        
            Male 
            Female 
 
11 (61.1)                                   
7 (38.9) 
 
19 (59.4)                                 
13 (40.6) 
 
8 (38.1) 
13 (61.9) 
 
 
38 (53.5) 
33 (46.5) 
Age (years)                                          
            median                                            
            range 
 
65 
49 - 79 
 
57.5                                
39 - 78 
 
62 
36 - 72 
 
 
59 
36 - 79 
Race                                                        
            Caucasian 
            Asian 
 
 
6 (33.3) 
12 (66.7) 
 
 
12 (37.5) 
20 (62.5) 
 
 
9 (42.9) 
12 (57.1) 
 
 
27 (38.0) 
44 (62.0) 
ECOG PS                        
            0 
            1   
                                             
 
5 (27.8) 
13 (72.2) 
 
 
15 (46.9) 
17 (53.1) 
 
 
8 (38.1) 
13 (61.9) 
 
 
28 (39.4) 
43 (60.6) 
Tumour site                                                       
            Colon 
            Rectum 
             
9 (50.0) 
9 (50.0) 
 
 
15 (46.9) 
17 (53.1) 
 
 
16 (76.2) 
5 (23.8) 
 
 
40 (56.3) 
31 (43.7) 
No. of previous lines of therapy                                           
            median                                            
            range 
 
2.5 
2 - 4 
 
2.5 
2 - 4 
 
3.0 
2 - 5 
 
 
3 
2 - 5 
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Table 2. Most common grade ≥3 drug-related toxicities and adverse event summary   
 Arm A 
N=18 (%) 
Arm B 
N=32 (%) 
Arm C 
N=21 (%) 
Difference  
Arm A vs. Arm C 
p-value (exact test) 
Difference  
Arm B vs. Arm C 
p-value (exact test) 
Neutropenia                                                  6 (33.3) 5 (15.6) 4 (19.0) 0.465 1.00 
Diarrhoea                                                    9 (50.0) 1 (3.1) 1 (4.8) 0.002 1.00 
Hyperglycaemia                                               2 (11.1) 3 (9.4) 1 (4.8) 0.586 1.00 
Dermatitis acneiform                                         0 (0) 3 (9.4) 2 (9.5) 0.490 1.00 
Rash                                                         2 (11.1) 1 (3.1) 0 (0) 0.206 1.00 
Fatigue                                                      3 (16.7) 2 (6.3) 0 (0) 0.089 0.512 
Asthenia                                                     1 (5.6) 2 (6.3) 1 (4.8) 1.00 1.00 
Hypokalaemia  2 (11.1) 1 (3.1) 0 (0) 0.206 1.00 
Patients with ≥1 toxicities 13 (72.2) 17 (53.1) 11 (52.4) 0.323 1.00 
Patients with SAE                                         13 (72.2) 14 (43.8) 10 (47.6) 0.192 1.00 
Drug-related SAE†  7 (38.9) 2 (6.3) 2 (9.5) 0.055 1.00 
Discontinuation‡ due to AE                  7 (38.9) 1 (3.1) 7 (33.3) 0.750 0.003 
Discontinuation‡ due to drug-related AE                              1 (5.6) 0 (0) 0 (0) 0.462 - 
Discontinuation‡ due to SAE                              5 (27.8) 1 (3.1) 6 (28.6) 1.00 0.012 
Discontinuation‡ due to drug-related SAE                              0 (0) 0 (0) 0 (0) - - 
Death within 60 days of trial entry 0 (0) 0 (0) 4 (19.0) 0.110 
 
0.020 
 
† Determined by the investigator to be related to the drug. 
‡ Study medication withdrawn.  
 
Abbreviations: AE, adverse event; SAE, serious adverse event. 
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Figures 
Figure 1. Progression-free survival (a) and overall survival (b) by treatment group  
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Figure 2. Box plots for IGF-1R expression according to location of primary tumour (a), KRAS 
status (b) or both (c) 
The y axis show median cycle threshold (Ct) values (log transformation). Ct values are inverse to the amount of 
mRNA, therefore lower values indicate high amounts of mRNA while higher values indicate lower amounts of 
mRNA.   
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Figure 3. Box plots for IGF-1 expression according to location of primary tumour (a), KRAS 
status (b) or both (c) 
The y axis show median cycle threshold (Ct) values (log transformation). Ct values are inverse to the amount of 
mRNA, therefore lower values indicate high amounts of mRNA while higher values indicate lower amounts of 
mRNA.   
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Figure 4. Box plots for IGF-2 expression according to location of primary tumour (a), KRAS 
status (b) or both (c) 
The y axis show median cycle threshold (Ct) values (log transformation). Ct values are inverse to the amount of 
mRNA, therefore lower values indicate high amounts of mRNA while higher values indicate lower amounts of 
mRNA.   
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Key for box plots  
 
 
 
                                  o     <- outside values 
                                  o 
 
           adjacent line  --+     -     <- upper adjacent value  (Q3+1.5(Q3-Q1)) 
                            |     | 
                  whiskers  |     | 
                           -|   +---+   <- 75th percentile (upper hinge) (Q3) 
                            |   |   | 
                     box    |   |---|   <- median (Q2) 
                            |   |   | 
                           -|   +---+   <- 25th percentile (lower hinge) (Q1) 
                  whiskers  |     | 
                            |     | 
           adjacent line  --+     -     <- lower adjacent value (Q1-1.5*(Q3-Q1)) 
 
                                  o     <- outside value 
 
 
